Specifically, PFS in NSCLC EGFR-mutant patients whose tumors do not significantly shrink after targeted therapy is rarely reported, contributing to the lack of comprehensive information about the treatment outcome of this subset of NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.